Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.9K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.9K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.7K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

2.7K
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
2.7K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

2.9K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.9K
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

2.5K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MT-MRI for detection of renal interstitial fibrosis in renovascular disease.

Scientific reports·2026
Same author

Clinical outcomes of TAVR with self-expanding valves for non- or minimally calcified aortic regurgitation.

Cardiovascular revascularization medicine : including molecular interventions·2026
Same author

Prognostic Value of Tricuspid Regurgitation in Pulmonary Hypertension and Among the Different WHO Groups.

JACC. Cardiovascular imaging·2026
Same author

Feasibility and Safety of Same-Day Discharge Following Elective Mitral Transcatheter Edge-to-Edge Repair.

JACC. Advances·2026
Same author

Real-World Outcomes of Transcatheter Tricuspid Valve Replacement: Analysis From the STS/ACC TVT Registry.

JAMA·2026
Same author

Hemodynamic and Clinical Outcomes of Transcatheter Valve Expansion in Degenerated Mitral Bioprostheses.

Circulation. Cardiovascular interventions·2026
Same journal

Implantable cardioverter-defibrillator in cardiac sarcoidosis: A propensity-score matched analysis.

Current problems in cardiology·2026
Same journal

Arterial Stiffness in Heart Failure with Preserved Ejection Fraction: is this a new Predisposing Factor?

Current problems in cardiology·2026
Same journal

The future of cardiovascular training: Bridging global disparities and building a hybrid model for equity in care.

Current problems in cardiology·2026
Same journal

Disparities in healthcare access and treatment outcomes for patients with chronic limb-threatening ischemia.

Current problems in cardiology·2026
Same journal

Diagnostic and prognostic value of coronary computed tomography angiography and high-risk plaque assessment in acute coronary syndrome.

Current problems in cardiology·2026
Same journal

Prognostic value of albuminuria in heart failure with preserved ejection fraction: A systematic review.

Current problems in cardiology·2026
See all related articles

Related Experiment Video

Updated: May 4, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.6K

Renal denervation for hypertension.

Mackram F Eleid, Gary L Schwartz, Rajiv Gulati

    Current Problems in Cardiology
    |January 14, 2014
    PubMed
    Summary
    This summary is machine-generated.

    Resistant hypertension, uncontrolled blood pressure despite medication, may be treated with renal denervation. This minimally invasive procedure shows promise for lowering blood pressure and reducing cardiovascular risks in affected patients.

    More Related Videos

    Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
    04:37

    Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

    Published on: June 6, 2025

    847
    A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
    08:21

    A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

    Published on: October 26, 2020

    4.9K

    Related Experiment Videos

    Last Updated: May 4, 2026

    Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
    08:35

    Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

    Published on: May 26, 2022

    3.6K
    Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
    04:37

    Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

    Published on: June 6, 2025

    847
    A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
    08:21

    A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

    Published on: October 26, 2020

    4.9K

    Area of Science:

    • Cardiovascular Medicine
    • Interventional Cardiology
    • Nephrology

    Background:

    • Hypertension is a primary global cause of mortality.
    • Resistant hypertension, defined as uncontrolled blood pressure despite multiple medications, significantly elevates cardiovascular mortality risk.
    • There is a critical need for novel therapeutic strategies for resistant hypertension.

    Purpose of the Study:

    • To evaluate the safety and efficacy of percutaneous catheter-based renal denervation for treating resistant hypertension.
    • To assess the potential of renal denervation to improve blood pressure control and reduce cardiovascular risk.
    • To explore the role of renal denervation in mitigating end-organ damage associated with resistant hypertension.

    Main Methods:

    • Percutaneous catheter-based renal denervation procedure.
    • Assessment of procedural safety.
    • Evaluation of blood pressure reduction over time (up to 2 years).

    Main Results:

    • Initial studies indicate the procedural safety of renal denervation.
    • Demonstrated effectiveness in reducing blood pressure for up to 2 years post-procedure.
    • Suggests potential benefits for cardiovascular risk reduction and end-organ damage.

    Conclusions:

    • Percutaneous catheter-based renal denervation is a promising treatment for resistant hypertension.
    • Further large randomized controlled trials are essential to confirm long-term efficacy and safety.
    • Renal denervation may offer a new therapeutic avenue for managing resistant hypertension and its complications.